We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others... Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge. Show more
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire LEXINGTON, Mass., April 5, 2024 LEXINGTON, Mass., April 5, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a...
Curis to Present at Upcoming Healthcare Conferences in April PR Newswire LEXINGTON, Mass., April 4, 2024 LEXINGTON, Mass., April 4, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a...
Curis Provides Fourth Quarter 2023 Business Update PR Newswire LEXINGTON, Mass., Feb. 8, 2024 Emavusertib data presented at ASH showed 3 of 5 patients achieved CR in R/R PCNSL Expansion of...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.25 | -1.6880486158 | 14.81 | 16.5 | 14.06 | 21724 | 15.31855194 | CS |
4 | 3.86 | 36.0747663551 | 10.7 | 17.49 | 10.02 | 42492 | 14.87005083 | CS |
12 | 5.04 | 52.9411764706 | 9.52 | 17.49 | 8.24 | 34459 | 11.95527917 | CS |
26 | 10.31 | 242.588235294 | 4.25 | 17.49 | 3.8 | 63882 | 10.24865927 | CS |
52 | -2.04 | -12.2891566265 | 16.6 | 19.6 | 3.8 | 165495 | 13.33934977 | CS |
156 | -197.44 | -93.1320754717 | 212 | 348 | 3.8 | 1405643 | 88.19072479 | CS |
260 | -21.04 | -59.1011235955 | 35.6 | 348 | 3.8 | 1642310 | 99.52274012 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions